Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer

• Main Authors: S. K. Zyryanov, M. Yu. Frolov, I. N. Dyakov
• Format: Article
• Language: Russian
• Published: ABV-press 2016-05-01
• Series: Onkourologiâ
• Subjects: kidney cancer; advanced renal cell carcinoma; targeted therapy; tyrosine kinase inhibitors; pazopanib; sunitinib
• Online Access: https://oncourology.abvpress.ru/oncur/article/view/562

Objective: to carry out a pharmacoeconomic analysis of using tyrosine kinase inhibitors for the targeted therapy of disseminated renal cell carcinoma.Materials and methods. The data on the efficacy and safety of therapy with tyrosine kinase inhibitors were obtained from the analysis of the results of clinical trials selected during an information search. The pharmacoeconomic analysis used the following methods: cost analysis, budget impact analysis, cost miniminization analysis, and sensitivity analysis.Results. The performed investigation demonstrated that the use of pazopanib in patients with disseminated renal cell carcinoma was expedient from an economic standpoint and less effective than that of sunitinib. The cost of an annual cycle of pazopanib treatment in Russia was not found to be greater than the payment readiness threshold. Analysis of the purchase amount of tyrosine kinase inhibitors for the treatment of renal cell carcinoma in 2014 demonstrated that the use of pazopanib could reduce government spending by 290.2 million (21.6%) rubles per year. This saving of budgetary funds provides a way of treating additional 375 people per 1,000 patients when using pazopanib. The administration of pazopanib with its existing purchase amount for the treatment of disseminated renal cell carcinoma will be able to reduce government spending by 1.4 milliard rubles during 5 years, which corresponds to the current annual costs of tyrosine kinase inhibitors.Conclusion. The use of pazopanib makes it possible to reduce government spending on 1st line targeted therapy of advanced RCC in comparison with sunitinib with comparable efficacy of both agents.